A clinical-stage biotechnology company developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system.
GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection | Business Wire
businesswire.com/news/home/2…
GenSight Biologics invite Julien Secheyron, « Patient N°15 » de la 1ère étude clinique de LUMEVOQ®, à venir présenter son livre « Vous ne verrez plus »
businesswire.com/news/home/2…
GenSight Biologics Announces Extension of Day 120 Clock Stop of LUMEVOQ® EMA Regulatory Filing; MAA Review to Resume in April 2022 | Business Wire
businesswire.com/news/home/2…
La start-up française @GenSightBio a mis au point une thérapie génique qui redonne leur autonomie aux patients atteints de la maladie de Leber, qui rend quasi-aveugle en quelques semaines nouvelobs.com/economie/20211… récit par @domnora
@GenSightBio announces that the peer reviewed journal International Ophthalmology Clinics has published a review of all current and past gene therapy trials for LHON. To read more, go to bit.ly/3uOOqfj#Clinicaltrials#LHON
Just published in the peer-reviewed International Ophthalmology Clinics
- Bilateral treatment effect following unilateral injection of #genetherapy independently reported by three research groups
- LUMEVOQ® for #LHON first #genetherapy requesting #maa#EMAjournals.lww.com/internat-op…